Taken together, our results suggest that the PI3K-Akt pathway is a major pathway target for CAPE treatment although CAPE treatment alone is not able to completely block PI3K/Akt signaling in human prostate cancer cells. This evidence concerns the gene AKT1 and Familial prostate cancer.